0001193125-22-107467.txt : 20220418 0001193125-22-107467.hdr.sgml : 20220418 20220418092459 ACCESSION NUMBER: 0001193125-22-107467 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220418 DATE AS OF CHANGE: 20220418 EFFECTIVENESS DATE: 20220418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kaleido Biosciences, Inc. CENTRAL INDEX KEY: 0001751299 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38822 FILM NUMBER: 22831163 BUSINESS ADDRESS: STREET 1: 18 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 617-674-9000 MAIL ADDRESS: STREET 1: 18 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 25 1 d315885d25.htm 25 25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-38822

 

 

KALEIDO BIOSCIENCES, INC.

THE NASDAQ GLOBAL SELECT MARKET

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

 

 

65 Hayden Avenue

Lexington, Massachusetts 02421

(617) 674-9000

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, par value $0.001 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

  ☐

17 CFR 240.12d2-2(a)(1)

 

  ☐

17 CFR 240.12d2-2(a)(2)

 

  ☐

17 CFR 240.12d2-2(a)(3)

 

  ☐

17 CFR 240.12d2-2(a)(4)

 

  ☐

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

 

  ☒

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Kaleido Biosciences, Inc.certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

Date: April 18, 2022    By:   

/s/ Theo Melas-Kyriazi

    Title: Director
   Name:    Theo Melas-Kyriazi